Select publications

Aldoss I et al. The toxicity profile of repeated doses of peg-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol 2015;[Epub ahead of print]. Abstract

Bigliardi S et al. Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: A retrospective monocenter study. Leuk Lymphoma 2014;[Epub ahead of print]. Abstract

Cortes J et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase trial (DASISION, CA180-056). Proc ASH 2014;Abstract 152.

Cortes JE et al. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up. Cancer 2015;121(10):1637-44. Abstract

DeAngelo DJ et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 2014;29(3):526-34. Abstract

Döhner H et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 2014;124(9):1426-33. Abstract

Flinn I et al. Preliminary results of a Phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Proc ASH 2014;Abstract 4687.

Freeman C et al. Risk factors associated with the development of infusion-related reactions in patients with chronic lymphocytic leukaemia treated with anti-CD20 monoclonal antibodies: Analysis of the CLL11 study dataset. Proc ASH 2014;Abstract 3339.

Goede V et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study. Leukemia 2015;29(7):1602-4. Abstract

Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370(12):1101-10. Abstract

Goede V et al. Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia and comorbidities: Results of the CLL11 study. Proc ASH 2014;Abstract 3327.

Greil R et al. Rituximab maintenance after chemoimmunotherapy induction in 1^st and 2^nd line improves progression free survival: Planned interim analysis of the international randomized AGMTCLL8/a Mabtenance trial. Proc ASH 2014;Abstract 20.

Grupp SA et al. T cells engineered with a chimeric antigen receptor targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL. Proc ASH 2014;Abstract 380.

Mahon FX et al. Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: The EURO-SKI study. Proc ASH 2014;Abstract 151.

O’Brien S et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: Results from the phase II RESONATE™-17 trial. Proc ASH 2014;Abstract 327.

O’Brien SG et al. Spirit 2: An NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML. Proc ASH 2014;Abstract 517.

Park JH et al. CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL. Proc ASH 2014;Abstract 382.

Platzbecker U et al. Improved outcome with ATRA-arsenic trioxide compared to ATRA-chemotherapy in non-high risk acute promyelocytic leukemia — Updated results of the Italian-German APL0406 trial on the extended final series. Proc ASH 2014;Abstract 12.

Rea D et al. Dasatinib or nilotinib discontinuation in chronic phase-chronic myeloid leukemia patients with durably undetectable BCRABL transcripts: Interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months — On behalf of the French CML Group Filmc. Proc ASH 2014;Abstract 811.

Roberts A et al. Determination of recommended Phase 2 dose of ABT-199 (GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia. Proc ASH 2014;Abstract 325.

Röllig C et al. Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: Results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial. Proc ASH 2014;Abstract 6.

Rousselot P et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32(5):424-30. Abstract

Santini V et al. Efficacy and safety of lenalidomide versus placebo in RBC-transfusion dependent patients with IPSS low/intermediate (int-1)-risk myelodysplastic syndromes without del(5q) and unresponsive or refractory to erythropoiesis-stimulating agents: Results from a randomized phase 3 study (CC-5013-MDS-005). Proc ASH 2014;Abstract 409.

Seymour JF et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015;126(3):291-9. Abstract

Sharman J et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG^®) plus rituximab for relapsed chronic lymphocytic leukemia: Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. Proc ASH 2014;Abstract 330.

Stock W et al. Favorable outcomes for older adolescents and young adults with acute lymphoblastic leukemia: Early results of US Intergroup trial C10403. Proc ASH 2014;Abstract 796.

Topp MS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16(1):57-66. Abstract

van Oers MHJ et al. Ofatumumab maintenance prolongs PFS in relapsed CLL: Prolong study interim analysis results. Proc ASH 2014;Abstract 21.